https://scholars.lib.ntu.edu.tw/handle/123456789/579171
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chang C.-Y. | en_US |
dc.contributor.author | Lai Y.-C. | en_US |
dc.contributor.author | Wei Y.-F. | en_US |
dc.contributor.author | CHUNG-YU CHEN | en_US |
dc.contributor.author | Chang S.-C. | en_US |
dc.date.accessioned | 2021-08-23T03:20:27Z | - |
dc.date.available | 2021-08-23T03:20:27Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1178-6930 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104100933&doi=10.2147%2fOTT.S290445&partnerID=40&md5=3b90cbd602c5d259f0b7df8cead039a9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/579171 | - |
dc.description.abstract | Background: Epidermal growth factor receptor (EGFR) mutations are most common in Eastern Asia, and frequencies of 30-50% have been reported. EGFR-tyrosine kinase inhibitors (TKIs) are recommended as first-line therapeutic options for non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. Several immune checkpoint inhibitors have been successful in improving the outcomes of advanced lung cancer. The expression of programmed cell death-ligand 1 (PD-L1) on tumor cells plays an important role in predicting the efficacy of programmed cell death protein 1/PD-L1 inhibitors. The role of PD-L1 expression in tumors with EGFR mutation and its influence on clinical outcomes remain controversial. Methods: Patients with newly diagnosed metastatic NSCLC with sensitizing EGFR muta- tions who received the standard treatment, ie, EGFR-TKIs for mutant adenocarcinoma as the first-line treatment, were enrolled in this retrospective study. EGFR mutations and PD-L1 expression levels were detected by Cobas RT-PCR and Dako 22C3 immunohistochemistry staining, respectively. Results: From January 2011 to February 2019, 114 patients were enrolled. The average age was 62 years (range 34-92), and 45 (39.5%) patients were male. Among these patients, EGFR mutation analysis revealed exon 19 in-frame deletion in 55 (48.2%) patients, exon 21 L858R in 53 (46.5%) patients, and uncommon mutations in 6 (5.3%) patients. Among these patients with EGFR mutations, PD-L1 expression levels by tumor proportion score (TPS) were <1% in 54 (46.9%) patients, 1-49% in 50 (44.2%) patients, and ?50% in 10 (8.8%) patients. All patients received EGFR-TKIs as first-line treatment, and in the Kaplan-Meier analysis, progression-free survival was not significantly different among groups with differ- ent PD-L1 expression status. Conclusion: For patients with metastatic NSCLC and EGFR mutations, PD-L1 expression is not uncommon, but no significant influence on clinical outcomes was observed in patients receiving standard initial treatment. ? 2021 Chang et al. | - |
dc.publisher | Dove Medical Press Ltd | - |
dc.relation.ispartof | OncoTargets and Therapy | - |
dc.subject | Epidermal growth factor receptor mutation; Epidermal growth factor receptor tyrosine kinase inhibitors; Programmed death-ligand 1 | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | afatinib; bevacizumab; epidermal growth factor receptor; erlotinib; gefitinib; programmed death 1 ligand 1; ramucirumab; adult; aged; Article; clinical outcome; EGFR gene; exon; female; gene deletion; gene mutation; human; major clinical study; male; metastasis; non small cell lung cancer; overall survival; progression free survival; protein expression; retrospective study; very elderly | - |
dc.title | PD-L1 expression and outcome in patients with metastatic non-small cell lung cancer and EGFR mutations receiving EGFR-TKI as frontline treatment | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.2147/OTT.S290445 | - |
dc.identifier.scopus | 2-s2.0-85104100933 | - |
dc.relation.pages | 2301-2309 | - |
dc.relation.journalvolume | 14 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine-NTUHYL | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.orcid | 0000-0001-9002-7255 | - |
crisitem.author.parentorg | National Taiwan University Hospital Yun-Lin Branch | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。